Brief: Prelude Therapeutics Q1 EPS USD -0.42 Vs. IBES Estimate USD -0.48
07/05/2024 12:01
May 07 (Reuters) - Prelude Therapeutics Q1 operating expenses USD 34.343 million. * Q1 income from operations USD -34.343 million * Q1 net income USD -31.431 million
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview